These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 14962898)

  • 1. The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin.
    Walter RB; Raden BW; Cronk MR; Bernstein ID; Appelbaum FR; Banker DE
    Blood; 2004 Jun; 103(11):4276-84. PubMed ID: 14962898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells.
    Walter RB; Raden BW; Hong TC; Flowers DA; Bernstein ID; Linenberger ML
    Blood; 2003 Aug; 102(4):1466-73. PubMed ID: 12689934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin.
    Linenberger ML; Hong T; Flowers D; Sievers EL; Gooley TA; Bennett JM; Berger MS; Leopold LH; Appelbaum FR; Bernstein ID
    Blood; 2001 Aug; 98(4):988-94. PubMed ID: 11493443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanism.
    Walter RB; Pirga JL; Cronk MR; Mayer S; Appelbaum FR; Banker DE
    Blood; 2005 Nov; 106(10):3584-93. PubMed ID: 16051742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Granulocyte colony-stimulating factor enhances the in vitro cytotoxicity of gemtuzumab ozogamicin against acute myeloid leukemia cell lines and primary blast cells.
    Rutella S; Bonanno G; Procoli A; Mariotti A; Lucia MB; Contemi AM; Cauda R; Fianchi L; Scambia G; Pagano L; Leone G
    Exp Hematol; 2006 Jan; 34(1):54-65. PubMed ID: 16413391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PK11195, a peripheral benzodiazepine receptor ligand, chemosensitizes acute myeloid leukemia cells to relevant therapeutic agents by more than one mechanism.
    Banker DE; Cooper JJ; Fennell DA; Willman CL; Appelbaum FR; Cotter FE
    Leuk Res; 2002 Jan; 26(1):91-106. PubMed ID: 11734307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3.
    Amico D; Barbui AM; Erba E; Rambaldi A; Introna M; Golay J
    Blood; 2003 Jun; 101(11):4589-97. PubMed ID: 12576328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nursing implications of mylotarg: a novel antibody-targeted chemotherapy for CD33+ acute myeloid leukemia in first relapse.
    Shannon-Dorcy K
    Oncol Nurs Forum; 2002 May; 29(4):E52-9. PubMed ID: 12011919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy.
    Walter RB; Gooley TA; van der Velden VH; Loken MR; van Dongen JJ; Flowers DA; Bernstein ID; Appelbaum FR
    Blood; 2007 May; 109(10):4168-70. PubMed ID: 17227830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemtuzumab ozogamicin: a review of its use in acute myeloid leukaemia.
    Fenton C; Perry CM
    Drugs; 2005; 65(16):2405-27. PubMed ID: 16266206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia.
    Arceci RJ; Sande J; Lange B; Shannon K; Franklin J; Hutchinson R; Vik TA; Flowers D; Aplenc R; Berger MS; Sherman ML; Smith FO; Bernstein I; Sievers EL
    Blood; 2005 Aug; 106(4):1183-8. PubMed ID: 15886328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin.
    Rosen DB; Harrington KH; Cordeiro JA; Leung LY; Putta S; Lacayo N; Laszlo GS; Gudgeon CJ; Hogge DE; Hawtin RE; Cesano A; Walter RB
    PLoS One; 2013; 8(1):e53518. PubMed ID: 23320091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk.
    Balaian L; Ball ED
    Leukemia; 2006 Dec; 20(12):2093-101. PubMed ID: 17051243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro experimental (211)At-anti-CD33 antibody therapy of leukaemia cells overcomes cellular resistance seen in vivo against gemtuzumab ozogamicin.
    Petrich T; Korkmaz Z; Krull D; Frömke C; Meyer GJ; Knapp WH
    Eur J Nucl Med Mol Imaging; 2010 May; 37(5):851-61. PubMed ID: 20107790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability.
    ten Cate B; Bremer E; de Bruyn M; Bijma T; Samplonius D; Schwemmlein M; Huls G; Fey G; Helfrich W
    Leukemia; 2009 Aug; 23(8):1389-97. PubMed ID: 19262596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemtuzumab ozogamicin and olaparib exert synergistic cytotoxicity in CD33-positive HL-60 myeloid leukemia cells.
    Yamauchi T; Uzui K; Nishi R; Shigemi H; Ueda T
    Anticancer Res; 2014 Oct; 34(10):5487-94. PubMed ID: 25275045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PK11195, an isoquinoline carboxamide ligand of the mitochondrial benzodiazepine receptor, increased drug uptake and facilitated drug-induced apoptosis in human multidrug-resistant leukemia cells in vitro.
    Jakubikova J; Duraj J; Hunakova L; Chorvath B; Sedlak J
    Neoplasma; 2002; 49(4):231-6. PubMed ID: 12382020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of gemtuzumab ozogamicin on acute myeloid leukemia blast cells in vitro, as a single agent and combined with other cytotoxic cells.
    Morris KL; Adams JA; Liu JA
    Br J Haematol; 2006 Nov; 135(4):509-12. PubMed ID: 17054677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of inducible multidrug resistance 1 expression in HL-60 cells resistant to gemtuzumab ozogamicin.
    Matsumoto T; Jimi S; Hara S; Takamatsu Y; Suzumiya J; Tamura K
    Leuk Lymphoma; 2012 Jul; 53(7):1399-405. PubMed ID: 22242821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse.
    Dowell JA; Korth-Bradley J; Liu H; King SP; Berger MS
    J Clin Pharmacol; 2001 Nov; 41(11):1206-14. PubMed ID: 11697753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.